Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


Vitae Pharmaceuticals, Inc.

Notes to the Financial Statements (Continued)

For the Years Ended December 31, 2013 and 2012

8. Convertible Preferred Stock and Stockholders' Equity (Continued)

Warrants

        As of December 31, 2013, the Company had 1,045,834 warrants outstanding for the purchase of preferred stock at exercise prices ranging from $0.90 - $1.20. The following table summarizes the warrants outstanding and exercisable as of December 31, 2013:

Warrants to Purchase
  Warrants
Outstanding
  Exercise
Price
  Expiration
Date
 

Series C convertible preferred stock

    33,334   $ 0.90     07/12/2016  

Series D convertible preferred stock

    325,000   $ 1.20     08/28/2018  

Series D convertible preferred stock

    687,500   $ 1.20     12/21/2021  

Shares Reserved for Future Issuance

        At December 31, 2013, the Company has reserved the following shares of common stock for issuance:

Common stock options outstanding

    29,716,795  

Restricted stock units outstanding

    9,000,000  

Shares available for future grant

    7,173,977  

Series A-1 preferred stock

    675,000  

Series A-2 preferred stock

    24,855,289  

Series B preferred stock

    151,112,779  

Series C preferred stock

    16,666,673  

Series D preferred stock

    25,000,000  

Warrants

    1,045,834  
       

    265,246,347  
       
       

9. Employee Compensation Plans

        In November 2013, the Company's Board approved the 2013 Stock Plan (the "2013 Plan") and reserved 12,205,519 shares of the Company's common stock to be authorized for issuance under the 2013 Plan. Under the 2013 Plan, options to purchase common stock, restricted stock and restricted stock units may be granted to the Company's employees, nonemployee directors, and consultants providing services to the Company. As of December 31, 2013, there are 7,173,977 shares available for grant without restriction.

        The Company has two additional share-based compensation plans pursuant to which outstanding awards have been made, but from which no further awards can or will be made: (i) the 2001 Stock Plan (the "2001 Plan"); (ii) the 2004 Stock Plan (the "2004 Plan"). In November 2013, the Company's Board authorized a decrease and to the shares available for issuance under the 2001 Plan by 12,205,519 shares and the automatic transfer of shares to the 2013 Plan from the 2001 and 2004 Plans that become available due to expiry, cancellation, termination or forfeiture. Through December 31, 2013, 3,968,458 shares became available under the 2001 Plan and were automatically transferred to the 2013 Plan.

        The Company's policy is to issue new common shares upon the exercise of stock options, conversion of share units or purchase of restricted stock. The 2013, 2004 and 2001 Plans (collectively, the "Plans") were approved and are administered by the Company's Board or its Compensation Committee.

F-25